Every material Form 8-K Zymeworks Inc. has filed with the SEC since August 25, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Zymeworks signed a Collaboration and License Agreement with Roche on October 22, 2026, giving Roche exclusive worldwide rights to develop and commercialize its ZW209 DLL3-targeting trispecific T-cell engager. The deal includes a $55 million upfront payment and up to $718 million in milestones, and it takes effect only after U.S. Hart-Scott-Rodino clearance, while Roche can terminate at any time.
Upfront non-refundable payment of $55 million, due after HSR Clearance
Non-refundable $40 million milestone on initiation of the Phase Ib Trial, plus up to $718 million in other milestones
Tiered high-single-digit to mid-teen royalties on annual net sales, with Zymeworks conducting the Phase Ia trial at Roche's expense
Roche may terminate the agreement in its sole discretion at any time; Zymeworks' exclusivity restriction runs up to five years
Zymeworks completed its acquisition of Theravance Biopharma on September 23, 2026, and issued $350 million of senior secured notes to fund part of the cash consideration and contingent value rights payments. The filing also sets out contingent value rights (CVRs) that give holders a share of certain future license proceeds, a $50 million milestone payment and a share of net sales, with the filing stating that payment is uncertain.
Notes carry a fixed 8.25% interest rate and mature December 31, 2036, with quarterly interest payments beginning December 2026.
The notes are guaranteed by Zymeworks subsidiaries and secured by a first-priority lien on substantially all of the issuers' and guarantors' personal property, subject to customary exclusions.
CVR holders may receive 80% of net license proceeds within 10 years, a $50 million milestone payment on first commercial sale of ampreloxetine in specified markets, and 10% of net sales; the filing calls these payments highly speculative.
Zymeworks will hold a conference call on Monday, September 28, 2026, at 8:30 a.m. Eastern Time.
Zymeworks announced that its partner Jazz Pharmaceuticals received FDA approval for two Ziihera regimens as first-line treatment of HER2-positive gastroesophageal adenocarcinoma. Zymeworks earned a $250 million milestone payment from Jazz on the approval and remains eligible for up to $1.3 billion in further milestones plus tiered royalties of 10% to 20% on Jazz's net sales. The filing does not report revenue, profit or guidance figures for the period.
FDA approved Ziihera plus tislelizumab and chemotherapy, and Ziihera plus chemotherapy, as first-line HER2+ GEA treatments, announced August 25, 2026
Zymeworks earned a $250 million milestone payment from Jazz; total payments from Jazz are $650 million to date
Zymeworks remains eligible for up to $1.3 billion in additional Jazz milestones and up to $144 million in BeOne milestones
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Zymeworks Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →